Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial

Open access
Janssens, Geert O., Rademakers, Saskia E., Terhaard, Chris H., Doornaert, Patricia A., Bijl, Hendrik P., van den Ende, Piet, Chin, Alim, Marres, Henri A., de Bree, Remco, van der Kogel, Albert J., Hoogsteen, Ilse J., Bussink, Johannes, Span, Paul N., Kaanders, Johannes H.·2012·Journal of Clinical Oncology

Abstract

Purpose: To report the results from a randomized trial comparing accelerated radiotherapy (AR) with accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in laryngeal cancer. Patients and Methods: Patients with cT2-4 squamous cell laryngeal cancer were randomly assigned to AR (68 Gy within 36 to 38 days) or ARCON. To limit the risk of laryngeal necrosis, ARCON patients received 64 Gy on the laryngeal cartilage. The primary end point was local control. Secondary end points were regional control, larynx preservation, toxicity, disease-free survival, and overall survival. In a translational side study, the hypoxia marker pimonidazole was used to assess the oxygenation status in tumor biopsies. Results: From April 2001 to February 2008, 345 patients were accrued. After a median follow-up of 44 months, local tumor control rate at 5 years was 78% for AR versus 79% for ARCON (P = .80), with larynx preservation rates of 84% and 87%, respectively (P = .48). The 5-year regional control was significantly better with ARCON (93%) compared with AR (86%, P = .04). The improvement in regional control was specifically observed in patients with hypoxic tumors and not in patients with well-oxygenated tumors (100% v 55%, respectively; P = .01). AR and ARCON produced equal levels of toxicity. Conclusion: Despite lack of benefit in local tumor control for advanced laryngeal cancers, a significant gain in regional control rate, with equal levels of toxicity, was observed in favor of ARCON. The poor regional control of patients with hypoxic tumors is specifically countered by ARCON treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.35.9315

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 256

Metadata

Authors
Janssens, G. O., Rademakers, S. E., Terhaard, C. H., Doornaert, P. A., Bijl, H. P., van den Ende, P., Chin, A., Marres, H. A., de Bree, R., van der Kogel, A. J., Hoogsteen, I. J., Bussink, J., Span, P. N., & Kaanders, J. H.
Venue
Journal of Clinical Oncology
Published
2012-05-20
Volume
30
Issue
15
Pages
1777-1783
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2163763232
Cited by
256
References
27
FWCI
25.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial. https://app.cochat.ai/papers/10.1200/jco.2011.35.9315
The paper
Janssens, G. O., Rademakers, S. E., Terhaard, C. H., Doornaert, P. A., Bijl, H. P., van den Ende, P., Chin, A., Marres, H. A., de Bree, R., van der Kogel, A. J., Hoogsteen, I. J., Bussink, J., Span, P. N., & Kaanders, J. H. (2012). Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.35.9315

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.